We demonstrated disease reversal for > 1 year by the AAV8‐hAAT‐FGF21 approach in HFD‐fed mice—the model that most closely resembles the metabolic characteristics of human obesity and insulin resistance—treated either as young adults or when older than 9 months. Here, FGF21 is linked to obesity disorder.